GlassScriptPhysician profile
Henry L Weiner
NPI 1821064775
$6,395.90
in general payments reported to CMS, 2019-2025
25 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,763 · 2020: $186 · 2021: $146 · 2022: $512 · 2023: $1,136 · 2024: $704 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964 · Travel and Lodging: $809 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.45 |
| Travel and Lodging | $808.84 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,620.87 | 2022-2025 | Micra, Selectsite, Linq II |
| Medtronic Vascular, INC. | $1,380.13 | 2019 | |
| Boston Scientific Corporation | $458.23 | 2019-2025 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor, Ingevity+ |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.74 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $390.25 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $383.13 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $360.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $284.27 | 2019-2024 | Brilinta |
| Pfizer INC. | $283.53 | 2019-2025 | |
| Abbott Laboratories | $187.28 | 2019-2025 | Aveir, Gallant |
| Sanofi-Aventis U.S. LLC | $144.53 | 2019-2022 | |
| Amgen INC. | $127.73 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $74.92 | 2019-2025 | |
| Bardy Diagnostics, INC. | $45.62 | 2019 | |
| Heartflow, INC. | $36.83 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $35.25 | 2021-2023 | Nexletol |
| Philips North America LLC | $33.51 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.68 | 2020-2025 | Lifevest |
| Biosense Webster, INC. | $26.68 | 2025 | Carto 3 |
| Lilly USA, LLC | $23.05 | 2025 | Mounjaro, Zepbound |
| Impulse Dynamics (USA) INC. | $21.60 | 2019 | |
| Preventice Services, LLC | $19.63 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.09 | 2024 | |
| Amarin Pharma, INC. | $13.06 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.